| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/05/2011 | EP2270498A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270225A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270224A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270223A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270222A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270221A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270220A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270219A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270218A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270217A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270216A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270215A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270214A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270213A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270212A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270211A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270210A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270144A1 Partial peptide of survivin presented on mhc class ii molecule and use thereof |
| 01/05/2011 | EP2270107A1 Compounds for Dual Photodiagnosis and Therapy |
| 01/05/2011 | EP2270055A2 Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component |
| 01/05/2011 | EP2270053A1 Humanized AXL antibodies |
| 01/05/2011 | EP2270050A1 Anti-CD19 antibodies with reduced immunogenicity |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270042A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270041A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270018A1 Antitumoral analogs |
| 01/05/2011 | EP2270011A1 Condensed imidazolo derivatives for the inhibition of aromatase |
| 01/05/2011 | EP2270010A1 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
| 01/05/2011 | EP2270008A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
| 01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
| 01/05/2011 | EP2269994A1 The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof |
| 01/05/2011 | EP2269993A1 2-aminoquinazoline derivative |
| 01/05/2011 | EP2269988A2 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP2269972A1 Oviedomycin derivatives, method for obtaining same and use thereof |
| 01/05/2011 | EP2269656A2 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
| 01/05/2011 | EP2269654A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 01/05/2011 | EP2269651A2 Stabilisation of macrolides |
| 01/05/2011 | EP2269619A1 Methods and compositions concerning poxviruses and cancer |
| 01/05/2011 | EP2269618A1 An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer. |
| 01/05/2011 | EP2269609A2 Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| 01/05/2011 | EP2269604A1 Treatment of solid tumours with rapamycin derivatives |
| 01/05/2011 | EP2269603A1 Treatment of solid tumours with rapamycin derivatives |
| 01/05/2011 | EP2269599A1 Chemically stable compositions of 4-hydroxy tamoxifen and their therapeutical applications |
| 01/05/2011 | EP2269580A2 Compositions comprising camptothecins in microspheres |
| 01/05/2011 | EP2268672A1 Anti-tyrp1 antibodies |
| 01/05/2011 | EP2268665A1 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity |
| 01/05/2011 | EP2268652A2 Platinum-n-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof |
| 01/05/2011 | EP2268637A1 Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors |
| 01/05/2011 | EP2268635A1 Heterocyclic compounds |
| 01/05/2011 | EP2268628A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 01/05/2011 | EP2268623A1 Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| 01/05/2011 | EP2268613A2 Inhibitors of cell proliferation and uses thereof |
| 01/05/2011 | EP2268604A1 Therapies for cancer using isotopically substituted lysine |
| 01/05/2011 | EP2268310A1 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
| 01/05/2011 | EP2268306A2 Therapeutic cancer antigens |
| 01/05/2011 | EP2268292A2 Method and compositions for treatment of cancer |
| 01/05/2011 | EP2268290A2 Styrene maleic anhydride based formulation for male contraception and prostate cancer |
| 01/05/2011 | EP2268287A1 Methods of administering antitumor agent comprising deoxycytidine derivative |
| 01/05/2011 | EP2268284A2 Use of g-rich oligonucleotides for treating neoplastic diseases |
| 01/05/2011 | EP2268273A1 Small-molecule modulators of trp-p8 activity |
| 01/05/2011 | EP2069404B1 Humanized anti-cd100 antibodies |
| 01/05/2011 | EP1881977B1 Histone deacetylase inhibitors |
| 01/05/2011 | EP1725233B1 Pharmaceutical composition comprising sns-595 and uses thereof |
| 01/05/2011 | EP1720882B1 Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors |
| 01/05/2011 | EP1546182B1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/05/2011 | EP1488796B1 Chromanol glucosides for ameliorating cancer chemotherapy |
| 01/05/2011 | EP1485415B1 Neoplasm specific antibodies and uses thereof |
| 01/05/2011 | EP1453471B1 Expression vectors encoding epitopes of antigens and methods for their design |
| 01/05/2011 | EP1446381B1 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP1401467B1 Alpha-fetoprotein peptides and uses thereof |
| 01/05/2011 | EP1294769B1 Antibodies that immunospecifically bind to blys |
| 01/05/2011 | EP1147214B1 A novel method for designing protein kinase inhibitors |
| 01/05/2011 | EP1128814B1 Aerosols comprising nanoparticle drugs |
| 01/05/2011 | CN1988934B Tetrahydropyridothiophenes |
| 01/05/2011 | CN1951952B Triterpene compound for preparing drug for treating cranial glia tumour |
| 01/05/2011 | CN1875944B A carbowax modified stealthy liposome nanosphere of hydroxycamtothecine and preparation method thereof |
| 01/05/2011 | CN1802388B CD20-specific antibodies and methods of employing same |
| 01/05/2011 | CN1703229B Compositions and uses for treatment of prostate and other cancers |
| 01/05/2011 | CN101939446A MicroRNA signatures in human ovarian cancer |
| 01/05/2011 | CN101939336A AXL antibodies |
| 01/05/2011 | CN101939326A Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof |
| 01/05/2011 | CN101939323A Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 01/05/2011 | CN101939319A Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| 01/05/2011 | CN101939314A Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
| 01/05/2011 | CN101939028A Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) |
| 01/05/2011 | CN101939027A Lipopeptides for delivery of nucleic acids |
| 01/05/2011 | CN101939020A Treatment of metastatic stage prostate cancer with degarelix |
| 01/05/2011 | CN101939008A Oral compositions of ABT-263 for treating cancer |
| 01/05/2011 | CN101939006A Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| 01/05/2011 | CN101939005A Kinesin inhibitors as cancer therapeutics |
| 01/05/2011 | CN101939001A Combination comprising paclitaxel for treating ovarian cancer |
| 01/05/2011 | CN101935651A siRNA module of targeted Survivin gene and application thereof |
| 01/05/2011 | CN101935650A siRNA (Small interfering Ribonucleic Acid) molecule for interfering Survivin expression and application thereof |
| 01/05/2011 | CN101935649A SiRNA (Small Interfering RNA) molecule capable of suppressing Survivin expression and application thereof |
| 01/05/2011 | CN101935358A Ganoderma lucidum polysaccharide and preparation method thereof |
| 01/05/2011 | CN101935353A Strepavidin/sCD40L fusion protein |
| 01/05/2011 | CN101935349A Humanized monoclonal antibody against human vascular endothelial growth factor and preparation and application thereof |
| 01/05/2011 | CN101935347A Deubiquitination mutant of mda-7/IL-24 |
| 01/05/2011 | CN101935336A Method for preparing water-soluble taxane medicament and application thereof |
| 01/05/2011 | CN101935334A Berberine glycyrrhetinic acid enantiomeric salts and preparation method and application thereof |